Synopsis
Synopsis
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 5' Nor Anhydrovinblastine
2. 5'-nor-anhydrovinblastine
3. Kw 2307
4. Kw-2307
5. Kw2307
6. Navelbine
7. Vinorelbine
8. Vinorelbine Tartrate
1. Vinorelbine Tartrate
2. 125317-39-7
3. Kw 2307
4. Navelbine (tn)
5. Vinorelbine Ditartrate (jan)
6. Vinorelbine Bitartarate
7. Vinorelbine Tartrate (usp)
8. Schembl4334811
9. Schembl16766511
10. Amy22244
11. S4269
12. Akos037748842
13. Ccg-270632
14. As-75352
15. D01935
16. Bis((2r,3r)-2,3-dihydroxybutanedioic Acid); Methyl (1r,9r,10s,11r,12r,19r)-11-(acetyloxy)-12-ethyl-4-[(12s)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0(3),(1)(1).0?,?]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0(1),?.0(2),?.0(1)?,(1)?]nonadeca-2(7),3,5,13-tetraene-10-carboxylate
Molecular Weight | 1079.1 g/mol |
---|---|
Molecular Formula | C53H66N4O20 |
Hydrogen Bond Donor Count | 10 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 16 |
Exact Mass | 1078.42704051 g/mol |
Monoisotopic Mass | 1078.42704051 g/mol |
Topological Polar Surface Area | 364 Ų |
Heavy Atom Count | 77 |
Formal Charge | 0 |
Complexity | 1820 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 11 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Vinorelbine tartrate |
Drug Label | Vinorelbine Tartrate Injection is for intravenous administration. Each vial contains vinorelbine tartrate equivalent to 10mg (1-mL vial) or 50 mg (5-mL vial) vinorelbine in Water for Injection, USP. No preservatives or other additives are present.... |
Active Ingredient | Vinorelbine tartrate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml |
Market Status | Prescription |
Company | Bedford; Hospira; Jiangsu Hansoh Pharm; Teva Pharms Usa; Actavis Elizabeth; Fresenius Kabi Usa; Hikma Maple; Ebewe Pharma; Dr Reddys Labs |
2 of 2 | |
---|---|
Drug Name | Vinorelbine tartrate |
Drug Label | Vinorelbine Tartrate Injection is for intravenous administration. Each vial contains vinorelbine tartrate equivalent to 10mg (1-mL vial) or 50 mg (5-mL vial) vinorelbine in Water for Injection, USP. No preservatives or other additives are present.... |
Active Ingredient | Vinorelbine tartrate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml |
Market Status | Prescription |
Company | Bedford; Hospira; Jiangsu Hansoh Pharm; Teva Pharms Usa; Actavis Elizabeth; Fresenius Kabi Usa; Hikma Maple; Ebewe Pharma; Dr Reddys Labs |
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-04-23
Pay. Date : 2016-03-23
DMF Number : 14619
Submission : 1999-12-13
Status : Active
Type : II
Certificate Number : R1-CEP 2011-342 - Rev 00
Issue Date : 2018-08-06
Type : Chemical
Substance Number : 2107
Status : Valid
Registration Number : 303MF10150
Registrant's Address : Rue Fonds Jean Pa(^)ques, 8 1435 Mont-Saint-Guibert Belgium
Initial Date of Registration : 2021-09-17
Latest Date of Registration : --
NDC Package Code : 69910-0004
Start Marketing Date : 2015-06-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-11-02
Pay. Date : 2015-06-11
DMF Number : 26091
Submission : 2013-12-30
Status : Active
Type : II
Certificate Number : CEP 2009-394 - Rev 06
Issue Date : 2024-04-11
Type : Chemical
Substance Number : 2107
Status : Valid
NDC Package Code : 62158-0001
Start Marketing Date : 2014-02-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9477
Submission : 1991-11-25
Status : Active
Type : II
Certificate Number : R1-CEP 2004-297 - Rev 05
Issue Date : 2020-02-25
Type : Chemical
Substance Number : 2107
Status : Valid
Registration Number : 218MF10576
Registrant's Address : 16 rue Jean Rostand ZI de Clergous 81600 GAILLAC FRANCE
Initial Date of Registration : 2006-06-15
Latest Date of Registration : --
Registrant Name : Bukwang Pharmaceutical Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-57-A-111-01
Manufacturer Name : Pierre Fabre Medicine
Manufacturer Address : Zone Industrielle des Clergous, 16 rue Jean Rostand - 81600 Gaillac, France
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19094
Submission : 2006-01-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9973
Submission : 1992-11-23
Status : Inactive
Type : II
Registrant Name : Bukwang Pharmaceutical Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-57-A-111-01
Manufacturer Name : Pierre Fabre Medicine
Manufacturer Address : Zone Industrielle des Clergous, 16 rue Jean Rostand - 81600 Gaillac, France
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Iran
Brand Name : Winobin
Dosage Form : Soft Gelatin Capsule
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Soft Gelatin Capsule
Dosage Strength : 20MG
Brand Name : Winobin
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Winobin
Dosage Form : Soft Gelatin Capsule
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Soft Gelatin Capsule
Dosage Strength : 30MG
Brand Name : Winobin
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Winobin
Dosage Form : Vial
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 10MG/ML
Brand Name : Winobin
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Winobin
Dosage Form : Vial
Dosage Strength : 50MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 50MG/5ML
Brand Name : Winobin
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Solution
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Solution
Dosage Strength : 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 10MG/Vial
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Packaging :
Regulatory Info :
Dosage : Liquid Injection
Dosage Strength : 10MG/Vial
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic
Registration Country : Argentina
Brand Name : VINOREL
Dosage Form : INJECTION
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number : 75992
Regulatory Info : Generic
Registration Country : Argentina
Packaging :
Regulatory Info : Generic
Dosage : INJECTION
Dosage Strength : 10MG
Brand Name : VINOREL
Approval Date :
Application Number : 75992
Registration Country : Argentina
Regulatory Info : Generic
Registration Country : Argentina
Brand Name : VINOREL
Dosage Form : INJECTION
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Argentina
Packaging :
Regulatory Info : Generic
Dosage : INJECTION
Dosage Strength : 50MG
Brand Name : VINOREL
Approval Date :
Application Number :
Registration Country : Argentina
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging :
Regulatory Info : Generic
Dosage : Injection
Dosage Strength : 50MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Portugal
Brand Name :
Dosage Form : Concentrate for soluti...
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Portugal
Packaging :
Regulatory Info :
Dosage : Concentrate for soluti...
Dosage Strength : 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Portugal
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Vinorelbine Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vinorelbine Tartrate, including repackagers and relabelers. The FDA regulates Vinorelbine Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vinorelbine Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Vinorelbine Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Vinorelbine Tartrate supplier is an individual or a company that provides Vinorelbine Tartrate active pharmaceutical ingredient (API) or Vinorelbine Tartrate finished formulations upon request. The Vinorelbine Tartrate suppliers may include Vinorelbine Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Vinorelbine Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Vinorelbine Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Vinorelbine Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Vinorelbine Tartrate DMFs exist exist since differing nations have different regulations, such as Vinorelbine Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Vinorelbine Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Vinorelbine Tartrate USDMF includes data on Vinorelbine Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vinorelbine Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Vinorelbine Tartrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Vinorelbine Tartrate Drug Master File in Japan (Vinorelbine Tartrate JDMF) empowers Vinorelbine Tartrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Vinorelbine Tartrate JDMF during the approval evaluation for pharmaceutical products. At the time of Vinorelbine Tartrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Vinorelbine Tartrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Vinorelbine Tartrate Drug Master File in Korea (Vinorelbine Tartrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vinorelbine Tartrate. The MFDS reviews the Vinorelbine Tartrate KDMF as part of the drug registration process and uses the information provided in the Vinorelbine Tartrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Vinorelbine Tartrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vinorelbine Tartrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Vinorelbine Tartrate suppliers with KDMF on PharmaCompass.
A Vinorelbine Tartrate CEP of the European Pharmacopoeia monograph is often referred to as a Vinorelbine Tartrate Certificate of Suitability (COS). The purpose of a Vinorelbine Tartrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Vinorelbine Tartrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Vinorelbine Tartrate to their clients by showing that a Vinorelbine Tartrate CEP has been issued for it. The manufacturer submits a Vinorelbine Tartrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Vinorelbine Tartrate CEP holder for the record. Additionally, the data presented in the Vinorelbine Tartrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Vinorelbine Tartrate DMF.
A Vinorelbine Tartrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Vinorelbine Tartrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Vinorelbine Tartrate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vinorelbine Tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vinorelbine Tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vinorelbine Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vinorelbine Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vinorelbine Tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vinorelbine Tartrate suppliers with NDC on PharmaCompass.
Vinorelbine Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vinorelbine Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vinorelbine Tartrate GMP manufacturer or Vinorelbine Tartrate GMP API supplier for your needs.
A Vinorelbine Tartrate CoA (Certificate of Analysis) is a formal document that attests to Vinorelbine Tartrate's compliance with Vinorelbine Tartrate specifications and serves as a tool for batch-level quality control.
Vinorelbine Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Vinorelbine Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vinorelbine Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Vinorelbine Tartrate EP), Vinorelbine Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vinorelbine Tartrate USP).
LOOKING FOR A SUPPLIER?